

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 3, 2003

Date of Deposit

Signature

EL 964841855 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **USST00004 US DIV**
INVENTORS: **MAURY, et al.**
TITLE: **FEBP1 PROTEIN VECTOR HOST CELLS AND METHOD FOR MAKING FEBP1 PROTEIN**

APPLICATION ELEMENTS

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. ☒ Specification
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

Total Pages

51

3. ☐ Drawing(s) (35 U.S.C. 113)

Total Sheets

4. Oath or Declaration

Total Pages

2

- a. ☐ Newly executed (original or copy)

- b. ☒ Copy of a combined Declaration and Power of Attorney from a prior application (37 CFR § 1.63(d))
(Submitted with U.S. Application Number 09/780,996 filed on February 9, 2001)

- i. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Power of Attorney

Total Pages

2

- a. ☐ Newly executed (original or copy)

- b. ☒ Copy of a combined Declaration and Power of Attorney from a prior application (37 CFR § 1.63(d))
(Submitted with U.S. Application Number 09/780,996 filed on February 9, 2001)

6. ☐ Microfiche Computer Program (*Appendix*)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☒ Statement Regarding Content Of Paper And Computer Readable Copies And
Reference To Another Application On File Pursuant To 37 C.F.R 1.821 (e) And (f)

- ☒ If a **CONTINUING Application**, check appropriate box, and supply the requisite information:
- ☐ Continuation ☒ Divisional ☐ Continuation-in-part
of prior application no: 09/780,996, filed February 9, 2001,
Examiner NICHOLS, Christopher J., Group/Art Unit 1647.
(The cross reference has been/will be inserted on page one of the specification).

- ☒ This application claims the benefit of U.S. Provisional Application No. 60/198,500,
filed April 18, 2000. (The cross reference has been/will be inserted on page one of the specification).

- ☒ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior
application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is
supplied, is considered as being part of the disclosure of the accompanying application and is
hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. ☐ Assignment Papers (*cover sheet & document(s)*)
8. ☐ 37 CFR §3.73(b) Statement
(*when there is an assignee*)
9. ☐ Verified English Translation Document (*if applicable*)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
11. ☒ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
13. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application,
(*PTO/SB/09-12*) Status still proper and desired
14. ☐ Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
15. ☒ Other: Application Data Sheet

CORRESPONDENCE ADDRESS

- ☒ Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626
Aventis Docket No. **USST00004 US DIV**

120303

1/23/03
U.S. PTO

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


**FEE TRANSMITTAL
for FY 2004**

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$ 770.00)****Complete if Known**

Application Number	Not yet Known
Filing Date	December 3, 2003
First Named Inventor	MAURY, et al.
Examiner Name	Not Yet Known
Group / Art Unit	Not Yet Known
Attorney Docket No.	USST00004 US DIV

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	3. ADDITIONAL FEES	
<input type="checkbox"/> Money Order	<input type="checkbox"/> Other		
<input type="checkbox"/> None			
<input checked="" type="checkbox"/> Deposit Account			
Deposit Account Number	18-1982		
Deposit Account Name	Aventis Pharmaceuticals Inc.		
The Commissioner is authorized to: (check all that apply)			
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input checked="" type="checkbox"/> Credit any overpayments		
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application			
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity	Small Entity		
Fee Code	Fee Code	Fee Description	Fee Paid
1001 770	2001 375	Utility filing fee	770
1002 340	2002 165	Design filing Fee	
1003 530	2003 260	Plant filing fee	
1004 770	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$770.00)			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			
Total Claims 1 - 20** = 18 x 18 = 324			
Independent 1 - 3** = 86 x 86 = 7396			
Claims			
Multiple Dependent			
Large Entity	Small Entity		
Fee Code	Fee Code	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 86	2201 42	Independent claims in excess of 3	
1203 290	2203 140	Multiple dependent claim, if not paid	
1204 86	2204 42	**Reissue independent claims over original patent	
1205 18	2205 9	**Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)			
**or number previously paid, if greater; For Reissues, see above			
Other fee (specify)			
Reduced by Basic Filing Fee Paid			
SUBTOTAL (3) (\$)			

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Joel B. German, Reg. No. 48,676	Registration No. (Attorney/Agent)	48,676
Signature		Telephone	(908) 231-3444
		Date	12/3/2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template